LucenceINSIGHT™ Cancer Screening
LucenceINSIGHT™ Cancer Screening is a Multi Cancer Early Detection (MCED) Test that screens for up to 50 different types of cancer in a simple blood draw.
LucenceINSIGHT™ harnesses the power of advanced genomics and artificial intelligence to detect cancer at its earliest stages. This innovative, non-invasive blood test identifies cancer biomarkers in the blood, enabling timely intervention and treatment.
To ensure a seamless and luxurious experience, LucenceINSIGHT™ is delivered with our signature white-glove service, offering you the highest level of personalised care and attention throughout the process.
The White-Glove Experience
Dedicated Concierge Support
Effortlessly access information and schedule your teleconsultation—all through the convenience of WhatsApp.
Doctor Consult
Understand the test pre- screening and discuss your results with our doctor at your convenience via teleconsultation.
Homebased Service
Complete your screening in comfort and privacy of your home, without any disruption to your schedule.
How Cancer Screening works?
Up to 50 Cancers Screened
1 Draw of Blood
12 - 18 Days To Results
LucenceINSIGHT™ Cancer Screening involves a simple blood draw, which is then analyzed using cutting-edge next-generation sequencing (NGS) technology. This technology detects genetic material from cancer cells, including DNA and RNA, in the blood. An AI-powered algorithm then interprets the results, providing a comprehensive report on the presence or absence of cancer biomarkers.
Cancer Screening Benefits
Early Detection
Detects cancer before symptoms appear, improving outcomes
Comprehensive
Detects up to 50 types of cancer, including lung, breast, colon, and more
Non-Invasive
No surgery or biopsy required, just a simple blood draw
Accurate
81% sensitivity and 99% specificity reduce false positives and negatives
Why Cancer Screen Early?
Numerous cancers can be detected early, often before symptoms appear. Regular early cancer screenings act as a proactive approach to ensure better care and treatment, minimizing complications and lowering medical costs. Optimal survival and recovery odds are associated with early-stage cancer diagnosis and treatment.
78% Cancer Deaths are Unscreened
4X Higher Survival with Early Diagnosis
Lower Medical Expenses
LucenceINSIGHT™ Packages
LucenceINSIGHT™
5
$999
(incl. gst)
5 Cancer Types
Lung (Small cell lung cancer, Non-small cell lung cancer)
Colorectal
Liver
Pancreatic
Thyroid
*Suitable for male and female
LucenceINSIGHT™
Women's 7
$1,299
(incl. gst)
7 Cancer Types
Lung (Small cell lung cancer, Non-small cell lung cancer)
Colorectal
Liver
Pancreatic
Thyroid
Breast
Ovarian
LucenceINSIGHT™
Women's 12
$1,999
(incl. gst)
12 Cancer Types
Lung (Small cell lung cancer, Non-small cell lung cancer)
Colorectal
Liver
Pancreatic
Thyroid
Breast
Ovarian
Stomach
Gastrointestinal stromal tumor (GIST)
Nasopharyngeal
Cervical
Endometrial
LucenceINSIGHT™
Men's 12
$1,999
(incl. gst)
12 Cancer Types
Lung (Small cell lung cancer, Non-small cell lung cancer)
Colorectal
Liver
Pancreatic
Thyroid
Bladder
Prostate
Stomach
Gastrointestinal stromal tumor (GIST)
Nasopharyngeal
Kidney (Clear cell)
Esophageal
LucenceINSIGHT™
50
$3,999
(incl. gst)
50 Cancer Types
Lung (Small cell lung cancer, Non-small cell lung cancer)
Colorectal
Liver
Pancreatic
Thyroid
Breast
Ovarian
Bladder
Prostate
Kidney (Clear cell)
Esophageal
Stomach
Gastrointestinal stromal tumor (GIST)
Cervical
Endometrial
Stomach Neuroendocrine Tumors
Colorectal Neuroendocrine Tumors
Ovarian Germ cell & Stromal Tumors
Lung Neuroendocrine Tumors
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
Hairy Cell Leukemia
Adult Wilms Tumor
Mast Cell Tumor
Small Intestine
Adrenal Gland
Biliary Tract
Soft Tissue
Myeloma
Testicular
Bone
Skin
Eye
Head
Neck
Vulvar
Penile
Frequently Asked Questions
Lucence Cancer Screening
LucenceINSIGHT™ serves as a comprehensive tool for early detection across a spectrum of up to 50 cancers, using a straightforward blood test. It identifies cancer-related changes in circulating DNA fragments, known as circulating tumor DNA (ctDNA), released by cancer cells into the bloodstream. Your report will indicate the presence or absence of these “Cancer Signals” as either “Detected” or “Not Detected,” allowing further assessment as needed.
Based on our proprietary next-generation sequencing technology, LucenceINSIGHT™ screens for the signal of cancer with a sensitivity of 80.9% and a specificity of 99%3.
Reference: https://insight.lucence.com/
Early cancer detection is recommended for everyone as a 78% of cancer-related deaths are not addressed by recommended screening methods. Statistics show that early diagnosis can enhance survival rates by up to four times. By identifying cancer at its earliest stages, treatment options are often more effective and less invasive, leading to improved chances of survival and a better quality of life for patients. Furthermore, early detection can empower individuals with the opportunity for proactive management and potentially prevent the disease from progressing to advanced stages.
References:
American Cancer Society. https://www.cancer.org/cancer.html
International Agency for Research on Cancer (IARC). Global Cancer Observatory. https://gco.iarc.fr/. 2020 Data, Accessed Dec 2022.
LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:
- Individuals aged 40 and above without personal history of cancer
- Individuals with elevated risk for cancer (eg, family history of cancer, diet, lifestyle etc)
Note: LucenceINSIGHT™ is not recommended for use in individuals who are pregnant, or have a history of cancer in the past 3 years.
LucenceINSIGHT™ examines changes in genes, which are like instructions for cell growth and function. Sometimes, alterations (mutations) in genes can make cells grow uncontrollably, leading to cancer.
In contrast, cancer marker tests like CA19-9 or CA-125 look for higher levels of specific proteins produced by cancer cells.
In summary, gene mutations and protein markers play a cause-and-effect role in cancer detection. LucenceINSIGHT™ complements routine cancer screening tools offer additional clarity in early cancer detection.
It’s typically recommended to have screenings annually.
Regular annual screenings play a vital role in detecting cancer at its earliest stages when treatment is often most effective. These screenings allow us to monitor any changes in your health and detect potential signs of cancer early on. We will determine the most suitable screening frequency based on your individual risk factors and medical history.
Results are typically available within 12 to 18 business days. We will contact you once the analysis is complete.
